Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
PepGen Inc. is a clinical-stage biopharmaceutical company specializing in the development of oligonucleotide therapeutics designed to treat severe neuromuscular and neurological disorders. Its most advanced candidate, PGN-EDO51 – an EDO peptide – is currently undergoing Phase 1 clinical trials for individuals suffering from Duchenne muscular dystrophy (DMD). The company's pipeline also includes PGN-EDODM1, an EDO peptide-conjugated PMO aimed at myotonic dystrophy type 1, alongside other EDO therapeutic candidates for DMD, specifically PGN-EDO53, PGN-EDO45, and PGN-EDO44. Established in 2018, PepGen Inc. operates from its headquarters in Cambridge, Massachusetts.
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers.
Target Price
The average target price of PEPG is 11 and suggests 613% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas